Background: A microRNA, miR499c, has been discovered in human fetal heart which rescues mutant hearts in cardiac nonfunction mutant axolotl (salamander) embryos and also induces the differentiation of mouse embryonic stem cells (mESCs) to form into definitive cardiomyocytes.
gulation of gene expression including regulation of cardiac development, cardiomyocyte proliferation and differentiation. They act to control the expression of sets of genes and fundamental regulatory pathways and are thought of as master regulators of gene expression. In a recent publication, Eulalio et al. showed that transduction of microRNAs in mouse hearts increases both DNA synthesis and induces cell proliferation [1] . In our recent publication we have reported the discovery of a novel form of microRNA, miR-499c, which rescues mutant hearts in salamander embryos [2] . The role of miR-499 in cardiomyocyte differentiation has been highlighted by several recent publications and it has been shown that miR-499 expression is significantly increased in differentiated cardiomyocytes [3] . Expression of miR-499 in human cardiac stem cells represses the miR-499 target genes, Sox6 and Rod1, enhancing cardiomyogenesis in vitro. Also, expression of miR-499 is significantly increased after myocardial infarction, suggesting that expression of miR-499 may provide an important protective mechanism against heart injury [3] . Another study demonstrated that miR-499 promotes the differentiation of mesenchymal stem cells into cardiomyocytes [4] . Thus, these data suggest that miR-499 plays a central role in cardiac development and differentiation.
Methods

RNA cloning
Random clones of 396 individual RNAs from human fetal heart were successfully acquired using the pDONR222 plasmid as a vector by routine procedures we have described earlier [2] . DNA clones were synthesized by PCR using the vectors as templates with M13 primers and the PCR products were visualized by agarose gel electrophoresis after ethidium bromide staining. The RNAs were synthesized by using an in vitro transcription reaction. RNA clones along with 0.1 mg/ml of lipofectamine transfection reagent were diluted to a concentration of 7 ng/μl in Opi-Mem media and transfected into the stem cells.
Stem cell culture protocol
Mouse Embryonic Stem Cells (mESCs, Strain 129, OriCell, Cyagen Biosciences, Inc., Santa Clara, CA) were incubated and grown on coverslips at 37°C and 5% CO2, and passaged routinely according to our published protocols [2] . To induce differentiation, the mouse cells were transfected with RNA derived from the active clones that had been mixed with the transfection reagent, Lipofectamine RNAiMAX (Life Technologies, Grand Island, NY), diluted to a concentration of 50 ng/µl in OPTI-MEM medium (Life Technologies, Grand Island, NY) and incubated for 6 hours.
qRT-PCR
Using a NucleoSpin RNAII Kit (Macherey-nagel, Bethlehem, PA), RNA was extracted from differentiated cells treated with the active RNA and controls were either untreated or treated only with lipofectamine. qRT-PCR was performed with a Rotor-Gene machine using a Rotor-Gene SYBR PCR kit (Qiagen, Valencia, CA) with primers designed as described in our earlier paper, Kochegarov et al [2] .
Immunohistochemistry
Cells grown on coverslips were fixed in 4% paraformaldehyde for 30 min, rinsed in PBS with 3% BSA for 3 min, permeabilized in 0.1% Tween-20 and 3% BSA and stained overnight at 4ºC with primary antibodies including: 1. monoclonal anti-tropomyosin CG3 antibody (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) diluted to 1:75; 2. anti-cardiac troponin antibodies (T 564766, BD Pharmingen, San Jose, CA), diluted to 1:100; 3. Anti-α-actinin antibodies (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) diluted 1:100. The cells on the coverslips were rinsed with PBS containing 3% BSA for 3 min and stained with FITC-labelled anti-mouse antibodies ((Abcam, Cambridge, MA) diluted to 1:75 for 2 hr at 4ºC. The coverslips with the attached cells were mounted on glass microscope slides with SlowFade® Gold antifade reagent (Invitrogen, Grand Island, NY) and viewed under an Olympus Fluorview laser scanning confocal microscope at an excitation of 488 nm and emission of 520 nm for FITC. The images were recorded using a computerized digital camera linked to the microscope.
Results
Mouse ESCs were cultured during multiple passages as undifferentiated colonies on matrigel (BD Biosciences, San Jose, CA) (Fig. 1A) . The passaged stem cells were placed in small "hanging drops" on Petri dish lids and incubated for 48 hours. After 48 hours, most of the stem cells had aggregated and formed embryoid bodies (EBs) (Fig. 1B) . We plated these EBs on collagen-coated culture dishes and allowed them to attach, grow and proliferate for an additional 48 hours (Fig.1C) . At this stage we treated the stem cells with RNA derived from the active miR-499c clone. After 8 days in culture most of the cells (75-80%) differentiated into cells with characteristic cardiomyocyte morphologies (Fig.1D ) and these cells showed significant staining for tropomyosin and cardiac specific troponin T and α-actinin (Figs. 1E, 3B, 4) . The quantity of cells that exhibited spontaneous cardiomyocyte differentiation without RNA treatment was less than 10% after 8 days in culture.
We also tested the ability of miR-499c to induce differentiation directly without the formation of EBs. We treated mouse embryonic stem cells daily for 6 hours with transfection medium containing the miR-499c followed by normal growth medium. The mouse embryonic stem cells differentiated into cardiomyocytes within 8 days showing changes into cardiomyocyte type morphologies and expressing cardiac troponin T in 75-80% of the cells. When the fluorescent staining intensity for tropomyosin was measured in the differentiating stem cells and converted into digital values by computer analysis, during the first seven days in culture the cellular tropomyosin increased progressively, strongly su- ggesting that the differentiation of the stem cells into cardiomycytes was taking place (Fig. 2) . Also after 7 days of treatment with mir499c, the stem-cells acquired characteristic cardiomyocyte morphologies (Fig. 3A) and showed tropomyosin (Figs. 3B, 4B), troponin T (Fig. 4A) and α-actinin  (Fig. 4C) incorporated into myofibrils indicative of definitive cardiomyocytes (Figs. 3B, 4) . In untreated controls, most of the stem cells became fibroblastlike in appearance without significant tropomyosin or troponin expression (Figs. 3C, 3D) . High resolution confocal imaging revealed myofibril organization after immunofluorecent staining for the cardiac specific troponin T, tropomyosin and α-actinin in mESC-derived cardiomyocytes treated with miR-499 (Fig. 4) . In our quantitative PCR studies, we examined the expression of various species of growth factors, Wnt, Sox and BmP, as well as the contractile proteins, troponin T, tropomyosin and myosin, with and without miR-499c treatment. We found that expression of Wnt11 and Sox17 increased significantly in response to the miR-499c treatment (Fig. 5) . Expression of other types of Wnt and Sox did not change significantly (not shown). Also with the expression of Wnt, cardiac marker contractile proteins including cardiac troponin T, tropomyosin and myosin increased significantly in 4 days and were at even higher levels after 8 days of the miR-499 treatment, corroborating the observations made using immunofluoresent confo- cal microscopy. Without miR-499c treatment, the Wnt11, Sox17, troponin T, tropomyosin and myosin did not increase significantly, but remained approximately at 0 day (base) levels (Fig. 5) .
Discussion
In recent studies we have identified a new precursor of a microRNA which we have called miR-499c [2] . This novel miR-499c sequence partially overlaps with both miR-499a and miR-499b and contains an additional short 22 base pair (bp) sequence. In our previous publication, we showed that this microR-NA promotes myofibrillogenesis and rescues mutant axolotl hearts by promoting the differentiation of non-muscle cells in the mutant myocardium into contracting cardiac muscle cells [2] . This fetal human heart microRNA appears to rescue the mutant axolotl hearts in a manner indistinguishable from our originally discovered axolotl myofibril inducing RNA (MIR) [5] . We hypothesize that these two RNAs promote myofibrillogenesis and rescue the mutant salamander hearts by binding and interacting with a common protein binding complex. They also induce differentiation of mouse embryonic stem cells. Spontaneous cardiomyocyte differentiation of mouse stem cells was described previously by Mummery et al. [6] . In that study, stem cells formed embryoid bodies (EBs) which then attached, proliferated and differentiated spontaneously. We found that spontaneous cardiomyocyte differentiation without RNA treatment was less than 10% and a large majority of these cells showed fibroblast-like shapes. Transfection of mouse ESCs with miR-499c significantly increased the formation of differentiated cardiomyocytes to 75-80% as revealed by immunohistochemical staining for cardiac specific troponin T, tropomyosin and α-actinin and by directing the cell morphologies into typical cardiomyocyte forms (Fig. 4) . We also tested the ability of miR-499c to induce stem cell differentiation directly without the formation of EBs. We treated mouse embryonic stem cells daily for 6 hours with transfection medium containing miR499c. In this experiment, stem cells differentiated into definitive cardiomyocytes in 8 days as revealed by positive immunofluorescent staining for cardiac troponin T and tropomyosin and by showing typical myocardial cell morphologies. Interestingly, during normal in vivo embryonic heart development in mouse, the first cardiac muscle tissue also appears on the 8th day of development. Thus, our data have clearly and unequivocally demonstrated the ability of our newly-discovered miR499c to rescue mutant hearts in axolotl embryos by forming cardiomyocytes from nonmuscle cells and by inducing the differentiation of mouse embryonic stem cells to form into cardiomyocytes. Our findings are supported further by recent publications which show that miR-499 induces the differentiation of mesenchymal stem cells into cardiomyocytes [4] . In another research study, miR-499 transduction into human embryonic stem cells significantly increased the yield of human embryonic ventricular cardiomyocytes (from 48% to 72%) along with increased contractile protein expression [7] . Further, it has been shown that miR-499 expression is significantly increased in differentiated cardiomyocytes [3] . Also, in our present study, expression of Sox6 did not show a statistically significant change with miR499c treatment, while expression of Sox11, which activates the non-canonical Wnt pathway, was significantly increased after 4 or 8 days. In addition, we found that Wnt11 expression correlated with an increase in expression of transcription factor Sox17. The research we report here, to our knowledge, is the first definitive evidence implicating Wnt11 as an important signal in cardiac differentiation. We hypothesize that Wnt11 may activate expression of the transcription factor, Sox17, which then initiates cardiac differentiation. Therefore, on the basis of our current results, one possible explanation is that in undifferentiated stem cells, transcription factors Oct 3/4 and Sox2 are expressed constitutively and bind to DNA to keep cells in a pluripotent condition, while in differentiating cells, Wnt11 activates expression of Sox17 and this in turn directs the cells to form into cardiomyocytes.
Of the many individuals worldwide who suffer heart attacks each year, there are a number of treatments that currently are used to reduce their symptoms and help in the recovery process. Although these interventions improve the quality of life for some, many do not fully recover because connective scar tissue replaces the cardiac muscle in the infarcted area and the heart loses its efficiency in pumping the blood. The research we report here may lead to better treatments for patients in the future who suffer from myocardial infarctions or other heart diseases that negatively affect myocardial tissue. It is possible that the use of MiR-499c, in combination with induced pluripotent stem cells derived from that same patient, could be used to repair the damaged cardiac muscle tissue, leading to a much better prognosis for heart-attack victims in the future.
Conclusion
We have found that MiR-499c promotes the differentiation of mouse ESCs into cardiomyocytes as well as rescues the development of mutant embryonic hearts in the salamander, Ambystoma mexicanum. MiR-499c appears to be an important regulator of vertebrate heart embryonic development and cardiomyocyte differentiation. This may take place by Wnt11 activating the expression of Sox17 which then directs the cells to differentiate into cardiomyocytes. Our findings may have important future clinical implications for the treatment of human heart damaged from myocardial infarction or other disease processes by replacing the damaged tissue with stem cells derived from the patient and induced to form into new myocardial cells using the active microRNA, miR-499c. The hope would be that such patients, with their hearts repaired by newly-formed myocardial cells, could return to a normal lifestyle again.
